Stock Evaluator: Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc. RVMD

$166.87 -5.42 -3.15%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 2,505,568
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Commentary & Analysis


Financial Summary

Share Statistics RVMD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $36,088.4 $202.9 91%
Shares Out (Mil) 214.9 55.4 77%
Institutional Ownership 97.8% 92.9% 75%
Float (Mil) 186.6 40.7 72%
Beta 1.43 1.04 80%
Avg Daily Volume (000s) 3,256 566 86%
Price Change
(52-week)
159.2% 41.0% 98%
Growth RVMD Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (59.9%) (10.3%) 5%
EPS (5yr) (24.2%) 15.8% 11
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (20.3%) (15.7%) 33%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 20 22 23
Current EPS ($1.087) ($8.271) ($3.152)
Month Ago EPS ($1.993) ($9.593) ($5.825)
# Rev Up 0 0 1
# Rev Down 1 1 0
Three Months Ago EPS ($2.031) ($9.564) ($6.601)
Year/Year Chg (42.7%) 39.0% (102.1%)
Financials RVMD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $198 $39 31%
Net Income (TTM) (Mil) ($1,871) ($44) 1%
EPS (TTM) ($9.139) ($1.400) 5%
Operating Cash Flow (TTM) (Mil) ($1,431) ($34) 1%
Net Cash Flow (TTM) (Mil) $409 ($1) 89%
Long-Term Debt (Q1) (Mil) $1,202 $4 68%
Enterprise Value (Q1) (Mil) $39,149 $144 90%
Valuation RVMD Industry
Median
Percentile
(All Stocks)
P/B 15.02 1.97 95%
P/E na 17.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios RVMD Industry
Median
Percentile
(All Stocks)
Gross Margin (634.6%) 67.6% 0%
Net Margin (946.8%) (50.6%) 0%
ROA (57.1%) (47.4%) 10%
ROE (93.6%) (53.5%) 9%
Liabilities to Assets 44.2% 29.7% 35%
F-Score 2 3 7%

Revolution Medicines, Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors